(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/045795 A3

(51) International Patent Classification:
A61K 31/165 (2006.01) *A61K 9/24* (2006.01)
A61K 31/41 (2006.01) *A61K 9/48* (2006.01)
A61K 45/06 (2006.01) *A61K 9/50* (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/US2008/077416

(22) International Filing Date:
24 September 2008 (24.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/975,919	28 September 2007 (28.09.2007)	US
60/975,909	28 September 2007 (28.09.2007)	US
60/975,901	28 September 2007 (28.09.2007)	US
60/975,925	28 September 2007 (28.09.2007)	US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **ALTENBURGER, Ralf** [DE/DE]; Muehleweg 9, 79591 Eimeldingen (DE). **BABIOLE SAUNIER, Maggy** [FR/FR]; 16 rue des champs, F-68130 Jettingen (FR). **BARGENDA, Nicole** [DE/DE]; Zum Meyerhof 7, 49196 Bad Laer (DE). **BOCK, Michaela, Anna, Maria** [DE/DE]; Rheinstrasse 14, 79104 Freiburg (DE). **ADLER, Sabine** [DE/DE]; Wölflinstrasse 5c, 79104 Freiburg (DE). **BUSS, Bruno** [DE/DE]; Wichernstr. 30, 27711 Osterholz-scharmbeck (DE). **CURDY, Catherine** [FR/CH]; Gotenstrasse 23, CH-4125 Riehen (CH). **GHOSH, Indrajit** [IN/US]; 130 New Road, K-19, Parsippany, NJ 07054 (US). **HIRSCH, Stefan** [DE/DE]; Theodor-Heuss-Strasse 21A, 79539 Lörrach (DE). **KELLER, Patrice, Francois** [FR/FR]; 29 rue de la Gare, F-68640 Muespach (FR). **KOCHHAR, Charu** [CH/CH]; Falkensteinerstrasse 40, CH-4053 Basel (CH). **LI, Shoufeng** [CN/US]; 20 Honeyman Road, Basking Ridge, NJ 07920 (US). **LOGGIA, Nicoletta** [IT/CH]; Schorenweg 32, CH-4058 Basel (CH). **MATHARU, Amol, Singh** [US/US]; 507 Timberbrooke Drive, Bedminster, NJ 07921 (US). **TAILLEMITE, Julien** [FR/FR]; 2 Quai du rhin, F-68330 Huningue (FR). **TONG, Wei-Qin** [US/US]; 1 Wellington Drive, Basking Ridge, NJ 07920 (US). **VIPPAGUNTA, Sudha** [IN/US]; 194 Patriots Road, Morris Plains, NJ 07950 (US). **WEN, Hong** [CN/US]; 22 Moss Avenue, Westfield, NJ 07090 (US). **WOLF, Marie-christine** [FR/FR]; Rue du Rhin 43, F-68300 St. Louis (FR). **LAKSHMAN, Jay, Parthiban** [US/US]; 169 Candlewick Lane, Bridgewater, NJ 08807 (US). **KOWALSKI, James** [US/US]; 38 Summit Road, Belle Mead, NJ 08502 (US).

(74) Agent: **FERRARO, Gregory, D.**; Novartis, Patent Department, One Health Plaza, Bldg. 104, East Hanover, NJ 07936-1080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
16 July 2009

(54) Title: GALENICAL FORMULATIONS OF ALISKIREN AND VALSARTAN

(57) Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.

WO 2009/045795 A3